PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Annual Report - A Deep Dive into 2025 Performance

In 2025, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PacBio) advanced its mission to revolutionize genomic sequencing. This summary, based on the company's Annual Report (Form 10-K), details its financial performance, operational milestones, and strategic direction for the fiscal year ended December 31, 2025.

Business Overview: PacBio, a leading life sciences company, develops, manufactures, and markets advanced sequencing systems. The company primarily focuses on its unique long-read SMRT (Single Molecule, Real-Time) sequencing technology, featured in its flagship Revio system, and its newer Onso short-read sequencing system. These platforms provide comprehensive genomic information for diverse applications, including human biomedical research, plant and animal sciences, and microbiology, aiming to expand PacBio's market share in genomics research and clinical applications.

Financial Performance Highlights (Fiscal Year 2025 vs. 2024 & 2023):

PacBio's total revenue reached $215 million in 2025, marking a 28% increase from $168 million in 2024 and a substantial rise from $130 million in 2023. Increasing adoption of the Revio long-read sequencing system and consistent consumable sales primarily drove this growth.

Despite this revenue growth, the company reported a net loss of $280 million in 2025. This represents a slight improvement from the $310 million net loss in 2024, yet still reflects substantial investments in research and development (R&D) and sales and marketing. Gross margin remained relatively stable at approximately 45%.

• Research & Development (R&D) expenses were $185 million in 2025, decreasing from $200 million in 2024, reflecting a post-restructuring strategic shift.
• Selling, General, and Administrative (SG&A) expenses were $150 million in 2025, decreasing from $165 million in 2024, also benefiting from efficiency initiatives.

Management Discussion (MD&A Highlights):

Strategic & Operational Developments:

1. Product Portfolio Expansion: PacBio prioritized commercializing its flagship Revio long-read sequencing system and the Onso short-read sequencing system to capture a broader market share in genomics research and clinical applications. Integrating technologies from the Apton and Omniome acquisitions (completed in 2021 and 2022) critically enhanced both long-read and short-read capabilities. These integrations contributed an estimated 10% to 2025 revenue through new product offerings and expanded market access.

2. Restructuring Initiatives: PacBio implemented significant restructuring efforts in 2024 and 2025. The 2024 restructuring, completed by Q2 2024, optimized R&D spending and streamlined commercial operations. This resulted in a one-time charge of $25 million and an estimated $30 million in annual operating expense savings starting in 2025. A subsequent, smaller restructuring in Q3 2025 further aligned resources with core strategic priorities, incurring an additional $10 million charge and projecting $15 million in annualized savings from 2026. The company took these actions to improve operational efficiency and accelerate its path to profitability.

3. Illumina Cambridge Limited Transaction: In January 2026, a notable event occurred after year-end: PacBio divested certain short-read sequencing intellectual property assets to Illumina Cambridge Limited for $75 million in cash. This transaction is expected to provide a cash injection without issuing new shares, allowing PacBio to further focus resources on its differentiated long-read sequencing technology and the Onso platform.

Financial Health:

As of December 31, 2025, PacBio held $350 million in cash, cash equivalents, and marketable securities. This amount is down from $420 million at the end of 2024, reflecting continued cash use for operations and strategic initiatives.

Capital Structure and Financing:

PacBio's balance sheet includes convertible notes, a key financing mechanism:

• The 2028 Convertible Notes (issued in 2021, $200 million outstanding) bear a 1.5% interest rate.
• The 2029 Convertible Notes (issued in 2022, $250 million outstanding) bear a 2.0% interest rate.
• The 2030 Convertible Notes (issued in 2023, $300 million outstanding) bear a 2.5% interest rate. These notes provide capital for operations and growth but also pose potential future dilution if converted into common stock, or a significant cash outflow if redeemed at maturity. The company had approximately 250 million shares of common stock outstanding as of December 31, 2025.

Key Risks Identified:

The company highlights several critical risks, including:

• Intense competition from established and emerging genomics companies.
• Reliance on successful commercialization and adoption of new products like Revio and Onso.
• Managing cash burn and achieving profitability.
• Intellectual property protection and litigation risks.
• Supply chain disruptions affecting manufacturing and product delivery.
• Regulatory changes in the life sciences industry.
• Potential dilution from future equity financing or conversion of convertible notes.

Competitive Position: PacBio operates in a highly competitive and rapidly evolving genomics market. Its primary competitors include large, established life sciences companies with broad sequencing technologies (e.g., Illumina in short-read sequencing) and emerging companies developing alternative platforms. PacBio differentiates itself through its unique long-read SMRT (Single Molecule, Real-Time) sequencing technology, which offers advantages for applications needing comprehensive genome analysis, detection of structural variants, and epigenetic modifications. While the Onso short-read system aims to expand PacBio's competitive presence, it faces intense competition in this segment. The company's ability to compete effectively depends on innovation, product performance, cost-effectiveness, and market adoption.

Future Outlook:

PacBio's 2025 performance shows a company in a growth phase, strategically investing in technology and market presence while actively managing operational efficiency through restructuring. The divestiture to Illumina Cambridge Limited further refines its strategic focus. The path to sustained profitability remains a key objective, with continued emphasis on increasing instrument placements, consumable sales, and disciplined expense management.